Cell and Gene Outsourcing

1. Trends Shaping The Future Of Cell And Gene Therapy Manufacturing 10/30/2025

   Discover how automation and digitalization are transforming cell and gene therapy with scalable, decentralized manufacturing and smarter market navigation.

2. Are You Still Evaluating CMOs When You Really Need A CDMO? 10/29/2025

   Outsourcing adds capacity and specialized knowledge to your supply chain. But contractors come in several types. Here's how to pick the right one.

3. Solving The Sequencing Puzzle: Speed, Cost, And Quality 10/28/2025

   Next-generation sequencing (NGS) accelerates therapy development by enabling rapid, cost-effective DNA/RNA analysis crucial for cell and gene therapies, process optimization, and impurity detection.

4. Optimizing CGT With Lean Principles 10/28/2025

   See the outline of lean manufacturing strategies for cell and gene therapies, emphasizing digitization, automation, and hybrid batch records to enhance efficiency and scalability.

5. Genetic Medicines, From Idea To Impact 10/28/2025

   This presentation explores how ElevateBio combines cutting-edge gene editing technologies with cell therapy and mRNA manufacturing expertise to enable partners through development and commercialization.

6. Opening New Frontiers In Genomic Medicine 10/28/2025

   This presentation highlights Life Edit, ElevateBio's gene editing and R&D business, boasting one of the world's largest gene editing toolboxes, advancing transformative medical innovations.

7. Rapid Analytics And Next Generation Sequencing 10/28/2025

   In vivo RNA optimization enhances liver gene editing by improving delivery, precision, and safety, which accelerates therapeutic development through advanced sequencing and integrated manufacturing technologies.

8. Achieve Efficient Viral Vector Production At Any Phase 10/28/2025

   The Challenge: Building Scalable Viral Vector Programs

   Cell and gene therapies offer unprecedented hope for previously untreatable diseases. At the heart of many of these advanced therapies, including both gene therapies and gene-modified cell therapies, are viral vectors, particularly Adeno-Associated Vectors (AAV) and Lentiviral Vectors (LVV), which serve as crucial gene-delivery vehicles.

9. Program Manager Alignment And Integration: Best Practices When Working With A CDMO 10/23/2025

   This Q&A discusses best practices for integrating program managers into a sponsor company and how program managers help bridge the gaps between various stakeholders.

10. A Strategic Enabler For Scaling Gene Therapies 10/22/2025

    Platform-based manufacturing uses standardized, pre-qualified workflows and analytics that reduce variability, simplify regulatory submissions, and accelerate the path to commercial success.